RVG29修饰脂质体对脑胶质瘤靶向性的初步研究

目的 研究一种新型配体RVG29修饰脂质体后,对体外脑胶质瘤的靶向性.方法 采用有机相合成法制备DSPE-PEG2000-RVG29 PPP(D-RVG29)材料,按照薄膜分散法制备脂质体,通过C6细胞和Hela细胞的细胞摄取考察D-RVG29修饰脂质体后,对体外脑胶质瘤的靶向性.结果 在脂质体处方中加入DSPE-PEG2000-OME(D-OME)可使D-RVG29修饰脂质体具有更好的粒径和分布范围,C6细胞对D-RVG29修饰脂质体的摄取强于未修饰D-RVG29的脂质体,Hela细胞对两种脂质体的摄取强度无明显区别.结论 D-OME可以提高D-RVG29修饰脂质体的稳定性,D-RVG29修饰脂质体具有体外脑胶质瘤细胞的靶向性.     

八聚精氨酸修饰的载紫杉醇脂质体的制备工艺研究

目的 研究八聚精氨酸(R8)修饰的载紫杉醇脂质体的制备工艺.方法 采用有机相反应法,将R8修饰到脂质体表面,并以薄膜分散-探头超声法制备载紫杉醇脂质体,以细胞摄取、粒径、PDI、包封率为主要指标对磷脂/胆固醇、药脂比、水化液种类、R8密度、DSPE-PEG2000密度进行筛选,进一步优化处方.结果 最优处方为磷脂-胆固醇2∶1、药脂比1∶40、水化液为PBS(pH6.5)、R8密度5％、DSPE-PEG2000密度3％,所制脂质体的粒径为156 ±2 nm,PDI＝ 0.25,包封率为80.87％±8.9％.结论 成功制备了八聚精氨酸(R8)修饰的载紫杉醇脂质体.     

甘草次酸修饰的阿霉素靶向脂质体的制备及体外抑瘤活性考察

目的：制备甘草次酸（GA）靶向阿霉素脂质体（GA-DOX-Lip）,并初步考察其体外抑瘤活性。方法：采用硫酸铵梯度载药法制备GA-DOX-Lip,单因素考察其处方工艺;采用微柱离心法和粒径仪考察脂质体包封率及其理化性质;通过荧光显微镜和流式细胞仪考察BEL-7402肝癌细胞对脂质体的摄取情况并用MTT法评价其体外杀伤效果。结果：GA-DOX-Lip形态圆整,粒径约为120 nm,包封率达到95%以上,72 h释放约20%;体外细胞摄取量和细胞杀伤效果均显著高于阿霉素普通脂质体。结论：甘草次酸修饰的脂质体有望成为肝肿瘤靶向的新型载体,促进抗肿瘤药物向肿瘤细胞内的递送。     

RGD类似物修饰的阿霉素隐形脂质体的制备及体外细胞结合试验

目的研究用精氨酸-甘氨酸-天冬氨酸(RGD)类似物(RGDm)修饰隐形脂质体(SL)，以增加抗癌药物在肿瘤部位积蓄的同时，增加抗癌药物向肿瘤细胞内的传递。方法合成RGDm，将其通过PEG链与二硬脂酰磷脂酰乙醇胺(DSPE)连接形成导向化合物DSPE-PEG-RGDm，在此基础上制备RGDm修饰的隐形脂质体(RGDm-SL)，阿霉素(DOX)作为模型药物通过硫酸铵梯度法装载。体外实验中，用pH探针(BCECF-AM)标记黑色素瘤细胞，通过细胞黏附试验考察导向化合物与肿瘤细胞的黏附情况；通过流式细胞实验和激光共聚焦显微实验考察肿瘤细胞对SL包封的阿霉素(SL-DOX)及RGDm-SL包封的阿霉素(RGDm-SL-DOX)的结合或摄取情况。结果与DSPE-PEG相比，黑色素瘤细胞与导向化合物DSPE-PEG-RGDm的黏附显著增加，过量游离RGDm的加入能抑制其黏附；与SL-DOX相比，RGDm-SL-DOX与黑色素瘤细胞共同孵育后，细胞对阿霉素的结合及摄取均显著增加。结论RGDm修饰的隐形脂质体可作为肿瘤靶向的载体通过受体介导的方式促进抗肿瘤药物向肿瘤细胞内的传递。     

枸橼酸二甲双胍阿霉素脂质体的制备

目的制备二甲双胍阿霉素脂质体并对其制备工艺进行优化。方法以二甲双胍阿霉素脂质体的包封率为评价指标,对其处方和制备工艺进行筛选和优化。分别考察了磷脂与胆固醇的比例、水化介质中阴离子的种类、水化介质的浓度、水化介质的pH值、载药温度、载药时间对二甲双胍阿霉素脂质体包封率的影响。结果最终优化的处方为m(hydrogenated soybean phosphatidylcho-line,HSPC)∶m(cholesterol,CH)∶m(polyethylene glycol 2000-cholesteryl hemisuccinate,mPEG2000-CHEMS)=3.0∶1.0∶1.0,以pH为7.00的300 mmol.L-1的枸橼酸二甲双胍为水化介质,60℃载药60 min,所制备的脂质体包封率可达98.7%。结论以枸橼酸二甲双胍离子梯度法制备的阿霉素脂质体包封率高,方法可行。     

星点设计-效应面法优化转铁蛋白修饰粉防己碱与硫酸长春新碱脂质体的处方

目的:制备转铁蛋白(TF)修饰粉防己碱(TET)与硫酸长春新碱(VCR)的主动靶向脂质体,优化其处方。方法:以硫酸铵梯度法制备TF修饰TET与VCR脂质体,以TET包封率、VCR包封率的综合评分为指标,用星点设计-效应面法优化卵磷脂/胆固醇(EPC/Chol)摩尔比、卵磷脂/聚乙二醇2000-二硬脂酰磷脂酰乙醇胺(EPC/PEG2000-DSPE)摩尔比、TF质量分数,并进行验证试验。结果:最优处方为EPC/Chol摩尔比1.5∶1,EPC/PEG2000-DSPE摩尔比20∶1,TF质量分数0.10%;所得脂质体TET包封率为97.80%,VCR包封率为93.00%,综合评分为94.44(n=3),与其预测值93.81接近。结论:优化所得处方稳定,可用于制备TF修饰TET与VCR脂质体。     

T7/A7R肽修饰的替莫唑胺脂质体制备与表征

摘要：目的:制备由T7、A7R肽双重修饰的替莫唑胺脂质体,并进行初步的体外表征。方法:分别将T7、A7R与DSPE-PEG2000-Mal反应生成DSPE-PEG2000-T7和DSPE-PEG2000-A7R,逆相蒸发法制备双肽修饰的脂质体（T7/A7R-LP）,并进行相应的体外表征。结果:制备的脂质体近球形,粒径均匀,平均粒径（96.6±6.5） nm, zeta电位为-（5.15±1.03） mV,包封率（36.38±3.95）%;在4～8℃条件下放置30 d,粒径和zeta电位无显著变化,体外6 h释药完毕;细胞摄取试验表明T7/A7R-LP具有较好的脑部靶向递送能力。结论:制备的T7/A7R肽修饰的脂质体理化特性良好,性质较为稳定,具有一定的脑部药物递送前景。     

RGD修饰载紫杉醇脂质体用于抗脑胶质瘤的体外研究

目的制备RGD修饰载紫杉醇脂质体并考察其体外抗脑胶质瘤治疗效果。方法采用薄膜分散法制备RGD修饰载紫杉醇脂质体（RGD—LP-PTX）,考察其理化性质。用鼠源性脑胶质瘤c6细胞考察肿瘤细胞对脂质体的摄取效率。MTT实验考察脂质体对肿瘤细胞的增殖抑制率。结果制备得到的RGD—LP粒径在120nm左右,PD,〈0.3。C6细胞对RGD．LP的摄取能力显著〉LP;RGD-LP-PTX对C6细胞的生长的抑制作用显著强于LP。结论经过RGD修饰后,脂质体具有良好的脑胶质瘤细胞靶向性,且能够显著增强栽药脂质体对脑胶质瘤细胞的增殖抑制作用。     

DSPE-PEG,Tween80和Brij35对伊文思蓝脂质体包封率和体内分布的影响

目的寻找与DSPE．PEG功能相似的表面活性剂，以增加脂质体的稳定性，改善其体内分布，提高靶向性。方法制备了伊文思蓝脂质体，考察了胆固醇与磷脂的比例对伊文思蓝脂质体包封率的影响；比较了用DSPE-PEG、Tween80和Brij35修饰后的伊文思蓝脂质体包封率和在大鼠体内分布状况的变化。结果伊文思蓝脂质体的包封率最高为25．30％。用DSPE-PEG、Tween80和Brij35修饰后使伊文思蓝脂质体的包封率略有下降，但差别不显著；体内分布实验结果显示：修饰后的脂质体在肝、脾和肾中伊文思蓝的浓度均有不同程度的降低，脑中伊文思蓝的浓度有所提高，而且以Tween80修饰组最显著。结论DSPE-PEG、Trween80和Brij35对伊文思蓝脂质体的包封率影响较小。Brij35对伊文思蓝脂质体的作用与DSPE-PEG相似，能提高脂质体逃避网状内皮系统吞噬的能力；Tween80主要能增加伊文思蓝脂质体在大鼠脑组织中的分布，为脑靶向脂质体的研究提供了有益信息。     

Box-Behnken效应面法优化主动靶向复方阿霉素/槲皮素脂质体

目的通过Box-Behnken效应面优化法筛选处方,制备生物素介导的阿霉素和槲皮素的复方脂质体。方法采用薄膜分散法制备槲皮素脂质体,通过硫酸铵梯度法主动包载阿霉素。分别以磷脂与胆固醇质量比(X1)、脂质与槲皮素质量比(X_2)、硫酸铵浓度(X_3)和孵育温度(X_4)为考察指标,以阿霉素(doxorubicin,DOX)包封率(Y_1,wEE/%)、槲皮素(quercetin,QUE)包封率(Y_2,wEE/%)及粒径(Y_3,d/nm)为评价指标;采用四因素三水平Box-Behnken效应面优化法筛选脂质体处方;测定优化脂质体的粒径、zeta电位和外观形态并考察脂质体的稳定性。结果最优化处方工艺为磷脂与胆固醇质量比为3.48∶1;磷脂与槲皮素质量比为26∶1;硫酸铵浓度为0.15 mol·L~(-1);阿霉素孵育温度为50℃;载药脂质体的平均粒径为148.5 nm;zeta电位为-23.1 m V;15 d内泄露率小于20%。结论采用Box-Behnken实验设计法优化处方所得数学模型预测性良好,可以用于复方阿霉素/槲皮素脂质体的处方优化。     

Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model

We report bifunctional liposomal delivery system, combining transferrin (Tf)-mediated receptor targeting and poly-L-arginine (PR)-facilitated cell penetration, which overcomes the drawback of saturation of delivery. PR was conjugated to the distal end of distearoyl phosphoethanolamine-polyethylene glycol (PEG) 2000 and was incorporated with other phospholipids in chloroform/methanol (2:1) to form PR liposomes using thin-film hydration technique. Tf-PEG phospholipid micelles were incorporated into PR liposomes using postinsertion technique to form Tf-PR liposomes. The bifunctional liposomes demonstrated significantly (p < 0.05) higher cellular uptake by brain endothelial cells (bEnd.3) and about eightfold higher transfection in primary culture of glial cells as compared with the Tf liposomes. Cell viabilities of Tf-conjugated and bifunctional liposomes were not markedly different; however, transport across in vitro blood-brain barrier model improved considerably after dual modification. The study underlines the potential of bifunctional liposomes as high-efficiency and low-toxicity gene delivery system for the treatment of central nervous system disorders.     

Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating

Abstract

In this study, glucose transporter and folic acid (FA) receptor-mediated Pluronic P105 polymeric micelles loaded with DOX (GF-DOX) were prepared for enhancing the blood–brain barrier (BBB) transportation and improving the drug accumulation in the glioma cells. The pH-triggered DOX release of GF-DOX indicating a comparatively fast drug release at weak acidic condition and stable state of the carrier at physiological environment. The transport of GF-DOX across the in vitro BBB model showed that GF-DOX exhibited higher BBB transportation ability with the transporting ratio of 21.47% in 4?h. The carrier was internalized into C6 glioma cells upon crossing the BBB model for the combined effect of the brain targeting by transportation of glucose transporter and active tumor cell targeting by FA receptor-mediated endocytosis. Moreover, minimized weight changes and high suppression ratio of tumor growth were observed after intravenous injection of GF-DOX. In conclusion, the glucose transporter and FA dual-targeting micelles would provide a safe and effective strategy for new modalities to treat brain tumor.     

Targeting liposomes with protein drugs to the blood-brain barrier in vitro.

In this study, we aim to target pegylated liposomes loaded with horseradish peroxidase (HRP) and tagged with transferrin (Tf) to the BBB in vitro. Liposomes were prepared with the post-insertion technique: micelles of polyethylene glycol (PEG) and PEG-Tf were inserted into pre-formed liposomes containing HRP. Tf was measured indirectly by measuring iron via atomic absorption spectroscopy. All liposomes were around 100 nm in diameter, contained 5-13 microg HRP per mumol phospholipid and 63-74 Tf molecules per liposome (lipo Tf) or no Tf (lipo C). Brain capillary endothelial cells (BCEC) were incubated with liposomes at 4 degrees C (to determine binding) or at 37 degrees C (to determine association, i.e. binding+endocytosis) and the HRP activity, rather than the HRP amount was determined in cell lysates. Association of lipo Tf was two- to three-fold higher than association of lipo C. Surprisingly, the binding of lipo Tf at 4 degrees C was four-fold higher than the association of at 37 degrees C. Most likely this high binding and low endocytosis is explained by intracellular degradation of endocytosed HRP. In conclusion, we have shown targeting of liposomes loaded with protein or peptide drugs to the BCEC and more specifically to the lysosomes. This is an advantage for the treatment of lysosomal storage disease. However, drug targeting to other intracellular targets also results in intracellular degradation of the drug. Our experiments suggest that liposomes release some of their content within the BBB, making targeting of liposomes to the TfR on BCEC an attractive approach for brain drug delivery.     

Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes

Cancer cells reflect higher level of ROS in comparison to the normal cell, so they become more vulnerable to further oxidative stress induced by exogenous ROS-generating agents. Through this a novel therapeutic strategy has evolved, which involves the delivery of redox cycler-doxorubicin (DOX) to the mitochondria of cancer cell where it acts as a source of exogenous ROS production. The purpose of this study is to develop a liposomal preparation which exhibits a propensity to selectively target cancer cell along with the potential of delivering drug to mitochondria of cell. We have rendered liposomes mitocancerotropic (FA-MTLs) by their surface modification with dual ligands, folic acid (FA) for cancer cell targeting and triphenylphosphonium (TPP) cations for mitochondria targeting. The cytotoxicity, ROS production and cell uptake of doxorubicin loaded liposomes were evaluated in FR (+) KB cells and found to be increased considerably with FA-MTLs in comparison to folic acid appended, mitochondria targeted and non-targeted liposomes. As confirmed by confocal microscopy, the STPP appended liposomes delivered DOX to mitochondria of cancer cell and also showed higher ROS production and cytotoxicity in comparison to folic acid appended and non-targeted liposomes. Most importantly, mitocancerotropic liposomes showed superior activity over mitochondria targeted liposomes which confirm the synergistic effect imparted by the presence of dual ligands - folic acid and TPP on the enhancement of cellular and mitochondrial delivery of doxorubicin in KB cells.     

培美曲塞-磷脂偶联物修饰的靶向性舒尼替尼与长春瑞滨脂质体的研制及其在体外对耐药性乳腺癌的抑制效应

乳腺癌是女性最易罹患的疾病,而肿瘤多药耐药性通常是化疗失败的主要原因。本研究以培美曲塞（PMT）和DSPE-PEG2000-NH2为原料合成了新的靶向性偶联物DSPE—PEG2000．PMT,并将其修饰到脂质体表面,制备了同时包封有舒尼替尼与长春瑞滨的靶向性脂质体,以增强化疗药物对多药耐药性乳腺癌的治疗效果。经过质谱分析证实,合成的靶向性载体材料DSPE．PEG2000-PMT与目标产物相符。建立了可同时检测舒尼替尼和长春瑞滨含量的高效液相色谱分析方法,检测波长为215nm,柱温30℃,流动相为乙腈-0．05MKH2P04（pH3．5）-三乙胺（35：65：0．3,v／v／v）。舒尼替尼和长春瑞滨的最低检测浓度分别为25ng／mL和5ng／mL,最低定量浓度均为0．25μg／mL。两药在0．5-25．0μg／mL范围内线性良好。各脂质体包封率均大于90％,粒径均-（～90nm）,Zeta电位略显负电性。在体外耐药乳腺癌MCF-7／Adr细胞中评价了靶向性舒尼替尼与长春瑞滨脂质体的抗增殖效应。结果显示,同对照组相比,靶向性舒尼替尼与长春瑞滨脂质体对MCF-7／Adr细胞具有最强的抑制增殖效应。以靶向性香豆素脂质体为荧光探针,考察了靶向性脂质体在耐药乳腺癌MCF-7／Adr细胞中的靶向性,同非靶向性制剂相比,靶向脂质体在耐药性癌细胞中摄取最多。因此,制备的靶向性舒尼替尼与长春瑞滨脂质体是-种新的靶向制剂,能够被耐药乳腺癌细胞靶向性摄取,可在体外显著抑制耐药性乳腺癌生长,从而为耐药乳腺癌的化学治疗提供了-种新的策略。     

The use of a new functional glucose conjugate material,TPGS1000-Glu,in treatment of brain glioma by incorporating into epirubicin liposomes

Most of anticancer agents can not be used for treatment of brain glioma due to the existence of the blood brain barrier (BBB). The over-expression of glucose transporters (GLUTs) on the BBB and brain glioma cells enables the possibility that the GLUTs ligand modified drug carrier transports across the BBB, and targets to the brain glioma cells. The objectives of the present study were to synthesize a new glucose conjugate material, TPGS₁₀₀₀-Glu, develop a kind of TPGS₁₀₀₀-Glu modified epirubicin liposomes, and evaluate their efficacy. The studies were performed on the BBB co-culture model and brain glioma cells in vitro. TPGS1000-Glu was synthesized by conjugating TPGS_1000-COOH with 4-aminophenyl-β-D-glucopyranoside (Glu), and confirmed by MALDI-TOF-MSspectrum. TPGS₁₀₀₀-Glu modified epirubicin liposomes were prepared with a high drug encapsulation efficiency (>97%), a nanosize (approximately 90 nm), and a minimal drug leakage in fetal bovine serum (FBS)-containing buffer system. The BBB co-culture model was established, and after applying TPGS₁₀₀₀-Glu modified epirubicin liposomes to the model, transport of liposomal drug across the BBB was evidenced. Besides, TPGS₁₀₀₀-Glu modified epirubicin liposomes showed the strongest cellular drug uptake and anti-glioma efficacy after transport across the BBB in vitro. The synthesized TPGS1000-Glu material could offer a new targeting ligand for the BBB, while the developed TPGS₁₀₀₀-Glu modified epirubicin liposomes might provide a potential anticancer formulation for treatment of brain glioma.     

Radioprotective effect of transferrin targeted citicoline liposomes

The high level of expression of transferrin receptors (Tf-R) on the surface of endothelial cells of the blood-brain-barrier (BBB) had been widely utilized to deliver drugs to the brain. The primary aim of this study was to use transferrin receptor mediated endocytosis as a pathway for the rational development of holo-transferrin coupled liposomes for drug targeting to the brain. Citicoline is a neuroprotective agent used clinically to treat for instance Parkinson disease, stroke, Alzheimer's disease and brain ischemia. Citicoline does not readily cross the BBB because of its strong polar nature. Hence, citicoline was used as a model drug. (Citicoline liposomes have been prepared using dipalmitoylphosphatidylcholine (DPPC) or distearoylphosphatidylcholine (DSPC) by dry lipid film hydration-extrusion method). The effect of the use of liposomes composed of DPPC or DSPC on their citicoline encapsulation efficiency and their stability in vitro were studied. Transferrin was coupled to liposomes by a technique which involves the prevention of scavenging diferric iron atoms of transferrin. The coupling efficiency of transferrin to the liposomes was studied. In vitro evaluation of transferrin-coupled liposomes was performed for their radioprotective effect in radiation treated cell cultures. In this study, OVCAR-3 cells were used as a model cell type over-expressing the Tf-R and human umbilical vein endothelial cells (HUVEC) as BBB endothelial cell model. The average diameter of DPPC and DSPC liposomes were 138 +/- 6.3 and 79.0 +/- 3.2 nm, respectively. The citicoline encapsulation capacity of DPPC and DSPC liposomes was 81.8 +/- 12.8 and 54.9 +/- 0.04 microg/micromol of phospholipid, respectively. Liposomes prepared from DSPC showed relatively better stability than DPPC liposomes at 37 degrees C and in the presence of serum. Hence, DSPC liposomes were used for transferrin coupling and an average of 46-55 molecules of transferrin were present per liposome. Free citicoline has shown radioprotective effect at higher doses tested. Interestingly, encapsulation of citicoline in pegylated liposomes significantly improved the radioprotective effect by 4-fold compared to free citicoline in OVCAR-3 but not in HUVEC. Further, citicoline encapsulation in transferrin-coupled liposomes has significantly improved the radioprotective effect by approximately 8-fold in OVCAR-3 and 2-fold in HUVEC cells with respect to the free drug. This is likely due to the entry of citicoline into cells via transferrin receptor mediated endocytosis. In conclusion, our results suggest that low concentrations of citicoline encapsulated in transferrin-coupled liposomes could offer therapeutic benefit in treating stroke compared to free citicoline.     

Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation

Staudinger ligation was evaluated as a strategy for synthesizing receptor targeted liposomes. First, an activated lipid derivative was synthesized by reacting dioleoyl phosphatidylethanolamine (DOPE) and 2-(diphenylphosphino) terephthalic acid 1-methyl 4-penta-fluorophenyldiester. Second, transferrin (Tf) was activated with p-azidophenyl isothiocyanate. Third, liposomes containing the activated lipid were prepared and then coupled to the activated Tf via the Staudinger reaction. These liposomes were evaluated in KB cells for cellular uptake and cytotoxicity, and in mice for pharmacokinetic properties. Tf-derivatized liposomes encapsulating calcein prepared by this conjugation method effectively targeted Tf receptor expressing KB cells. In addition, the Tf-targeted liposomes entrapping doxorubicin showed greatly enhanced in vitro cytotoxicity relative to non-targeted control liposomes. Pharmacokinetic parameters indicated that these liposomes retained long circulating properties relative to the free drug. In summary, Staudinger ligation is an effective method for the synthesis of receptor targeted liposomes.     

Synergistic tumor microenvironment targeting and blood–brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy

Cancer associated fibroblasts (CAFs) which shape the tumor microenvironment (TME) and the presence of blood brain barrier (BBB) remain great challenges in targeting breast cancer and its brain metastasis. Herein, we reported a strategy using PTX-loaded liposome co-modified with acid-cleavable folic acid (FA) and BBB transmigrating cell penetrating peptide dNP2 peptide (cFd-Lip/PTX) for enhanced delivery to orthotopic breast cancer and its brain metastasis. Compared with single ligand or non-cleavable Fd modified liposomes, cFd-Lip exhibited synergistic TME targeting and BBB transmigration. Moreover, upon arrival at the TME, the acid-cleavable cFd-Lip/PTX showed sensitive cleavage of FA, which reduced the hindrance effect and maximized the function of both FA and dNP2 peptide. Consequently, efficient targeting of folate receptor (FR)-positive tumor cells and FR-negative CAFs was achieved, leading to enhanced anti-tumor activity. This strategy provides a feasible approach to the cascade targeting of TME and BBB transmigration in orthotopic and metastatic cancer treatment.     

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma

Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and ^DA7R dual peptides-modified liposomes (abbreviated as T7/^DA7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma. ^DA7R is a d-peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/^DA7R-LS showed the most favorable antiglioma effect in vivo. In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy.